Compare Danaher Corporation (DHR) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Vanguard Short Term Corporate Bond ETF — how do they compare? Danaher Corporation trades at $205.83 (market cap $144.67B), while Vanguard Short Term Corporate Bond ETF trades at $78.6. The key difference: Danaher Corporation pays a 0.78% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Danaher Corporation is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| DHR | VCSH | |
|---|---|---|
Market Cap | $144.67B | — |
Sector | Health | Fixed Income |
52-Week High | $242.05 | $80.20 |
52-Week Low | $161.91 | $78.41 |
Enterprise Value | $166.88B | — |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $207.44, down 0.87% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company demonstrates solid fundamentals with consistent earnings beats in recent quarters and a healthy 15.95% net income margin. Recent developments include the Masimo acquisition approval and new product launches in the SCIEX division, supporting growth prospects in biotechnology and life sciences segments.
DHR presents a mixed outlook with strong analyst support (69% buy ratings) but faces valuation concerns at a P/E of 36.98. Key opportunities include biotechnology segment growth and strategic acquisitions, while risks involve elevated valuation, competitive pressures, and potential market volatility. The stock trades above the consensus price target of $202.33, suggesting limited near-term upside despite positive fundamentals.
VCSH trades at $78.58, up 0.11% today, with a bearish technical signal from moving averages but neutral oscillators. The ETF maintains a 4.8% yield with recent dividends of $0.29-$0.30, though credit spreads are tight. News highlights institutional activity, including Apella Capital reducing its stake by 5.6% in Q2 2026 (SEC filing, August 7, 2026).
Outlook is cautious due to unattractive entry points and limited upside from rate cuts, per Seeking Alpha (July 27, 2026). Risks include credit spread widening and competition from alternatives like BSV. The short 2.7-year duration offers some downside protection, but yield advantages may narrow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
